On October 16, 2026, Recursion Pharmaceuticals, a clinical-stage company using AI-enabled drug discovery and development, closed an underwritten public offering of 61,540,000 shares of its Class A common stock at a public offering price of $3.25 per share. The gross proceeds from the offering were approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.

The Wilson Sonsini team that advised Recursion on the transaction included Patrick Schultheis, Jeana Kim, Ashley Schmidt, Hanna Kim, Kathryn Obermiller, and Naman Patel.

For more information, please see Recursion’s news release.